BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. announced a poster presentation showing research results for mTNX-1700 at the Seventh International Cancer Immunotherapy Conference 2023 : Translating Science into Survival, being held September 20-23, 2023, in Milan, Italy.

Affimed N.V. announced that its Chief Financial Officer, Angus Smith, will participate in a fireside chat at the Cantor Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 1:15 p.m. Eastern Daylight Time / 19:15 Central European Time.

LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today launched a partnership with ASCEND Therapeutics US, LLC , a subsidiary of Besins Healthcare and a specialty pharmaceutical company concentrating on women’s health, to provide integrated telehealth services to improve access to EstroGel ® 0.06% (estradiol gel).

NewAmsterdam Pharma Company N.V. announced initial data from its Phase 2a clinical trial evaluating obicetrapib in patients with early Alzheimer’s disease and at least one copy of the apolipoprotein E4 mutation.

Antengene Corporation Limited today announced that a Phase I study of the best-in-class anti-CD24 antibody, ATG-031, has been approved by the Institutional Review Board (IRB) of The University of Texas MD Anderson Cancer Center in Houston, Texas, the United States.

Mesoblast Limited provided an update on the path to approval for its lead-product candidate remestemcel-L in the treatment of pediatric and adult steroid-refractory acute graft versus host disease, following a Type A meeting held with the United States Food and Drug Administration.

CARsgen Therapeutics Holdings Limited announced the publication of two cases of the treatment of metastatic pancreatic cancer with CARsgen’s CT041, an innovative Claudin 18.2 CAR T-cell Therapy, in Journal of Hematology & Oncology, titled “CT041 CAR T cell therapy for Claudin18.2–positive metastatic pancreatic cancer”.

Apnimed, Inc. today announced the first patient dosed in its LunAIRo Phase 3 study designed to examine the efficacy and safety of AD109 (aroxybutynin/atomoxetine) compared to placebo at six-months and one year.

Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.

Sensorion is pleased to announce it is hosting a webconference on September 25, 2023, and its participation in two upcoming investor conferences in October 2023.